Mouse Anti-HAVCR2 Recombinant Antibody (clone F38-2E2) (CAT#: HPAB-0192-LSX)

Figure 1 Mixed lymphocyte reaction on day 1 or day 7 following treatment with F38-2E2, mAb15 or an isotype control.

Supernatants were assessed for their expression of IL-1β, TNFα and IFN-γ at the time points indicated.

Figure 2 Expression of GM-CSF (FIG. A) and IL-6 (FIG. B) from activated macrophages from two different donors one day following treatment with anti-TIM-3 antibodies. Controls included F38-2E2, a commercially available anti-TIM-3 antibody and mIgG isotype controls.

Figure 3 PBMC from a donor with low LILRB2 showed diminished modulation of GM-CSF, IL-1β, and TNFα expression with mAb15 compared to F38-2E2.

Donor KP42331 expressed LILRB2 (left panel, top). Donor KP42334 showed low expression of LILRB2 (left panel, bottom). Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 and anti-TIM-3 antibody mAb15. mIgG1 served as an isotype control.

Figure 4 Dose curve of release of IL-1β from macrophages stimulated by LPS following treatment with different doses of antibodies.

Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (squares) and anti-LILRB2 (clone 287219) (inverted triangles). mIgG1 isotype (diamonds) and no antibody (triangles) served as a negative control. Data were collected at 24 hr, 48 hr, and 3 days post-treatment as indicated.

Figure 5 A graph demonstrating a dose curve of release of IL-1β from macrophages stimulated by LPS following treatment with different doses of antibodies.

Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (diamonds), and commercially available anti-LILRB2 antibody (clone 287219) (triangles). Data were collected at day 1-post-treatment. Data were normalized.

Figure 6 A graph demonstrating a dose curve of release of TNFα from macrophages stimulated by LPS following treatment with different doses of antibodies.

Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (diamonds), and commercially available anti-LILRB2 antibody (triangles). Data were collected at day 3 post-treatment. Data were normalized.

Figure 7 A graph demonstrating a dose curve of release of TNFα from macrophages stimulated by HMGB-1 following treatment with different doses of antibodies.

Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles) and anti-TIM-3 antibody mAb15 (squares). Data were normalized.

Figure 8 Graphs demonstrating release of IL-1β (FIGS. A), TNFα (FIGS. B) and IL-6 (FIGS. C) from macrophages stimulated by HMGB-1.